Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ecolab Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.57 (market cap $772.39M), while Ecolab Inc. trades at $281.36 (market cap $77.96B). The key difference: Ecolab Inc. is far larger — about 100.9× Ginkgo Bioworks Holdings Inc's market cap, and Ecolab Inc. pays a 1.05% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Ecolab Inc. for 90 Days on average.
| DNA | ECL | |
|---|---|---|
Market Cap | $772.39M | $77.96B |
Volume | 6,453,273 | 1,145,536 |
Sector | Health | Basic Materials |
52-Week High | $15.83 | $308.35 |
52-Week Low | $5.48 | $245.73 |
Typical Hold Time | 7 Days | 90 Days |
Enterprise Value | $874.34M | $86.74B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Ecolab (ECL) trades at $281.69, up 0.31% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $326.38. The company reported revenue of $16.08B in 2025 with a net income margin of 12.57%, and recent earnings have mostly met or exceeded expectations. Strong institutional buying and insider purchases, alongside positive news coverage highlighting its dividend growth and essential business model, support a constructive outlook.
The stock presents a favorable risk-reward profile given its steady revenue growth, high profitability, and analyst optimism, though elevated valuation ratios and increased debt from the CoolIT acquisition pose risks. The upcoming Q3 2026 earnings report on October 27, 2026, will be a key catalyst for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
